News
MRUS
--
0.00%
--
DJ Merus Initiated at Outperform by William Blair
Dow Jones · 3d ago
Insider Trends: 90-Day Buying Trend Extended with Insider Purchase of Merus NV Stock
MT Newswires · 04/01 17:34
Insider Trends: Insider Purchase Continues Merus NV Positive Trend
MT Newswires · 03/24 17:20
Merus gibt Finanzergebnisse fur das vierte Quartal und Gesamtjahresergebnisse fur das Jahr 2020 bekannt und legt ein Update zur Geschaftsentwicklung vor
Update der klinischen Daten und des Programms fur den fuhrenden Produktkandidaten Zenocutuzumab ("Zeno") im zweiten Quartal 2021 geplant
Globe Newswire · 03/18 20:16
Insider Trends: 90-Day Buying Trend Extended with Insider Purchase of Merus NV Stock
MT Newswires · 03/18 18:21
Analyst Actions: HC Wainwright Adjusts Merus' Price Target to $30 from $23, Maintains Buy Rating
MT Newswires · 03/17 12:07
DJ Merus Is Maintained at Sector Perform by RBC Capital
Dow Jones · 03/17 12:03
DJ Merus Price Target Raised to $21.00/Share From $15.00 by RBC Capital
Dow Jones · 03/17 12:03
RBC Capital Maintains Sector Perform on Merus, Raises Price Target to $21
RBC Capital analyst Brian Abrahams maintains Merus (NASDAQ:MRUS) with a Sector Perform and raises the price target from $15 to $21.
Benzinga · 03/17 11:54
DJ Merus Price Target Raised to $30.00/Share From $23.00 by HC Wainwright & Co.
Dow Jones · 03/17 10:45
DJ Merus Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/17 10:45
--Analyst Actions: RBC Boosts Price Target on Merus to $21 From $15, Maintains Sector Perform-Speculative Risk Rating
MT Newswires · 03/17 08:17
Merus N.V. (MRUS) Reports Q4 Loss, Tops Revenue Estimates
Zacks.com · 03/16 22:15
Merus Announces Financial Results for the Fourth Quarter and Full Year 2020 and Provides Business Update
Clinical data and program update planned for lead program zenocutuzumab (“Zeno”) in 2Q 2021 Clinical update planned for MCLA-145 in 2H 2021 MCLA-129 expected to enter clinic in the United States in 2021 UTRECHT, The Netherlands and CAMBRIDGE, Mass., March ...
GlobeNewswire · 03/16 21:57
Merus EPS misses by $0.28, beats on revenue
Merus (MRUS): FY GAAP EPS of -$2.92 misses by $0.28.Revenue of $29.94M (-3.8% Y/Y) beats by $1.31M.Press Release
Seekingalpha · 03/16 21:15
DJ Merus Initiated at Outperform by SVB Leerink
Dow Jones · 03/16 11:07
DJ Merus Price Target Announced at $33.00/Share by SVB Leerink
Dow Jones · 03/16 11:07
--Analyst Actions: SVB Leerink Starts Merus at Outperform With $33 Price Target
MT Newswires · 03/16 08:30
Merus kundigt Poster-Prasentationen fur Zenocutuzumab und MCLA-129 auf der Jahrestagung der American Association for Cancer Research 2021 an
UTRECHT, Niederlande und CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V.(Nasdaq: MRUS) ("Merus", "das Unternehmen", "wir" oder "unser"), ein Unternehmen aus dem Bereich der klinischen Onkologie, das innovative multispezifische volllange A...
Globe Newswire · 03/10 21:45
Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2021 Annual Meeting
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® ...
GlobeNewswire · 03/10 21:45
Webull provides a variety of real-time MRUS stock news. You can receive the latest news about Merus through multiple platforms. This information may help you make smarter investment decisions.
About MRUS
Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.